Phase I Adjuvant Trial of Sorafenib in Hepatocellular Carcinoma Patients After Liver Transplantation.
Phase of Trial: Phase I
Latest Information Update: 16 May 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 18 May 2011 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center).
- 30 Sep 2010 Additional lead trial investigator (Edward Lin) identified as reported by ClinicalTrials.gov. (NCT00844168)
- 21 Sep 2010 Planned end date changed from Jan 2014 to Jan 2015 as reported by ClinicalTrials.gov (NCT00844168).